Merck's Keytruda cuts progression or death risk 43% in trial for dMMR endometrial cancer
MRK•Keytruda reduced the risk of progression or death by 43% versus chemotherapy in a Phase 3 trial of patients with dMMR advanced or recurrent endometrial cancer. Overall survival showed a favorable trend, and severe treatment-related adverse events were less frequent with Keytruda.
1. Trial results
Merck said Keytruda monotherapy significantly improved progression-free survival versus chemotherapy in Phase 3 KEYNOTE-C93, which enrolled patients with dMMR advanced or recurrent endometrial cancer. Overall survival showed a favorable trend, with follow-up ongoing; severe treatment-related adverse events were less frequent with Keytruda, and no new safety signals emerged.
2. Next steps
The results are being presented at the ESMO Congress 2026 and were published simultaneously in The Lancet. Merck said it will submit the findings to regulators worldwide.
